| Home | E-Submission | Sitemap | Editorial Office |  
Korean J Urol Oncol > Volume 11(2); 2013 > Article
The Korean Journal of Urological Oncology 2013;11(2): 105-108.
전이성 거세 저항 전립선암에서 Docetaxel 전신 화학요법의 최적의 횟수
안성훈, 박승철
원광대학교 의과대학 비뇨기과학교실
Optimal Cycles of Docetaxel-Based Systemic Chemotherapy in Men with Metastatic Castration-Resistant Prostate Cancer (CRPC)
Sung Hoon Ahn , Seung Chol Park
Department of Urology, Wonkwang University School of Medicine, Iksan, Korea
Published online: August 30, 2013.
Metastatic prostate cancer is initially treated with androgen deprivation therapy, which induces rapid decrease in bone pain and decrease in serum prostate specific antigen level. However, most of cases with prostate cancer eventually progress to castration-resistant prostate cancer within a median of 18-24 months. Docetaxel-based systemic chemotherapy is now the standard treatment for CRPC, based on the results of 2 phase III studies. However, the optimal cycles of docetaxel-based systemic chemotherapy for CRPC has not been defined. Herein, we present two cases of castration-resistant prostate cancer treated by docetaxel-based systemic chemotherapy and reviewed recent literatures. (Korean J Urol Oncol 2013;11:105-108)
Key Words: Prostate cancer; Chemotherapy
Editorial Office
Department of Urology, Chung-Ang University Hospital
102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-1819   Fax: +82-2-6294-1406   E-mail: journal@kjuo.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Urological Oncology Society and The Korean Prostate Society. All rights reserved.                 Developed in M2PI
Close layer
prev next